ERBB2 and gastric cancer: Moreover, the TRIO-013/LOGiC trial evaluated the efficacy of lapatinib in combination with standard chemotherapy in patients with HER2-positive advanced GC as a first-line treatment, but lapatinib did not improve patient OS compared with placebo (mOS 12.2 vs. 8.9 months; P = 0.349); however, OS was significantly prolonged in Asian and younger patients (< 60 years) in an exploratory analysis [91].